Oaktree Acquisition Corp II News - OACB

Alvotech erwartet Markteinführung von AVT02 (Adalimumab) in den USA am 1. Juli 2023, vorbehaltlich behördlicher Genehmigung Alle laufenden...

Alvotech estime que l’AVT02 (adalimumab) sera commercialisé aux États-Unis le 1er juillet 2023, sous réserve des autorisations...

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023 All ongoing U.S. disputes...

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933...

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to...

UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 13GUnder the Securities Exchange Act of 1934 OAKTREE...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act...

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to...

Alvotech Holdings S.A. (« Alvotech »), l’une des principales entreprises biopharmaceutiques à l’échelle mondiale, axée uniquement sur le...

Das weltweit tätige biopharmazeutische Unternehmen Alvotech Holdings S.A. (kurz „Alvotech“), das sich ausschließlich auf die Entwicklung und...

false 0001820931 Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fourth of one redeemable warrant 0001820931...

Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar...

Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of...

Filed by Oaktree Acquisition Corp. II (Commission File No. 001-39526) Pursuant to...

trueQ3Oaktree Acquisition Corp. II0001820931--12-31CA36.1 0001820931 2021-01-01 2021-09-30 0001820931 2020-12-31 0001820931 2021-09-30...